Everything below concerns PNB-0408. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
March: Decree on feudal successions, abolishing primogeniture and affirming gender equality in inheritance. May–June: Decree establishing relief workshops for beggars, differentiated by sex, age, and health (women and children assigned to spinning rather than agricultural workshops). August: Requirement for public prosecutor's hearing if a married woman (or ward, minor, or legally incapacitated person, male or female) is involved in judicial proceedings.
=== Other === Around 30% of people have swollen, painful joints, but this is generally mild. Later in the course of the disease, patients often experience difficulty swallowing, called dysphagia, which makes it hard to move food from the mouth to the stomach. The muscles of the esophagus may become weak, leading to reduced or irregular movements that prevent proper swallowing. Additionally, individuals might suffer from gastroesophageal reflux disease (GERD), where stomach acid flows back into the esophagus, causing heartburn and irritation.
In the 1930s and later, epidemiologists from Japan, the UK, and the US, including Richard Doll and various others, reported greater rates of death from lung cancer following occupational exposure to PAH-rich environments among workers in coke ovens and coal carbonization and gasification processes.
On 19 December, the National Guard stated that Syrian government forces in Rimat Hazim and Al-Mazra'a launched attacks towards Al-Majdal with drones and mortar fire, injuring two civilians, in addition to an infiltration by Syrian government forces on the northwest axis, resulting in four wounded. The National Guard accused Tareq al-Shoufi of "collaborating with Sharaa, and [he] went into hiding", while al-Hijri was "accused of kidnapping and his son of dealings with regional drug-smuggling networks, including Hezbollah." On 23 December, the National Guard stated that the Syrian government forces had “continued their attacks against al-Jabal and the surrounding areas”, using mortar fire, heavy machine guns, and drones. The city of Attil was attacked with mortar fire from Rimat Hazem and Tel Hadid, causing two deaths and eight injuries. There was also an attack on the civilian prison of Suwayda and transport directorate using heavy machine guns and mortar fire. On 24 December, clashes occurred between the National Guard and the Syrian government forces on the Ara-Khirbet Samar axis in the rural area of Suwayda and on the al-Majdal-al-Mazra'a axis, using 23mm heavy machine guns. That same day, the Royal Jordanian Air Force launched attacks on Suwayda that targeted “a series of factories and workshops that drug and arms traffickers use as bases to launch their illegal operations into Jordanian territory", It also attacked seven sites under the control of the National Guard, including a suspected weapons depot in Al Kafr, belonging to the Suwayda Military Council.
Sources: en.wikipedia.org
==== Positional scanning ==== Positional scanning was introduced independently by Furka et al. and Pinilla et al. The method is based on the synthesis and testing of series of sublibraries, in which a certain sequence position is occupied by the same amino acid. The figure shows the nine sublibraries (B1-D3) of a full peptide trimer library (A) made from three amino acids. In sublibraries, there is a position which is occupied by the same amino acid in all components. In the synthesis of a sublibrary, the support is not divided and only one amino acid is coupled to the whole sample. As a result, one position is really occupied by the same amino acid in all components. For example, in the B2 sublibrary, position 2 is occupied by the "yellow" amino acid in all the nine components. If, in a screening test, this sublibrary gives a positive answer, it means that position 2 in the active peptide is also occupied by the "yellow" amino acid. The amino acid sequence can be determined by testing all nine (or sometime less) sublibraries.
Most paleontologists have always accepted that Tyrannosaurus was an active predator and, like most large carnivores, would also opportunistically scavenge. By far the largest carnivore in its environment, T. rex was most likely an apex predator, preying upon hadrosaurs, armored herbivores like ceratopsians and ankylosaurs, and possibly sauropods (such as Alamosaurus). Enamel δ44/42Ca values also suggest the possibility that T. rex occasionally fed on carcasses of marine reptiles and fish washed up on the shores of the Western Interior Seaway. A study in 2012 by Karl Bates and Peter Falkingham found that Tyrannosaurus had the most powerful bite of any terrestrial animal that has ever lived, finding an adult Tyrannosaurus could have exerted 35,000 to 57,000 N (7,868 to 12,814 lbf) of force in the back teeth. Even higher estimates were made by Mason B. Meers in 2003. This allowed it to crush bones during repetitive biting and fully consume the carcasses of large dinosaurs. Stephan Lautenschlager and colleagues calculated that Tyrannosaurus was capable of a maximum jaw gape of around 80 degrees, a necessary adaptation for a wide range of jaw angles to power the creature's strong bite. A discredited fringe hypothesis that was never seriously considered was that Tyrannosaurus was an obligate scavenger. The argument originated in a 1917 study by Lambe which argued that large theropods were pure scavengers because Gorgosaurus teeth showed hardly any wear. This argument disregarded the fact that theropods rapidly replaced their teeth.
=== Genesis of the Israelite people === Biblically, the Israelites referred to the descendants of Israel, a view that was reinforced by Second Temple Judaism, although gentiles could fully assimilate into the Israelite community. They referred to themselves as the sons of Israel, which could possibly refer to peoplehood rather than blood descent, especially after Israel's biological family transitioned from a clan to a nation (Exodus 1:9). The Israelite identity is alternatively interpreted as being based on religious allegiance, especially through worship of Yahweh or 'covenantal circumcision'. There's also contentious evidence of Israelite tribal status being acquired through self-declared allegiance, residency within assigned tribal territory (Ezekiel 47:21–23) or forceful absorption by a greater Israelite tribe. Jason A. Staples argues that the Israelites referred to the northern Israelite tribes, especially in the Nevi'im, although it's also inclusive of the other tribes in other contexts. The Israelites trace their ancestors to Jacob, who in turn descended from Abraham. Abraham was formerly a native of Ur Kaśdim (Genesis 11:31), whose location is unknown. Some scholars argue that it is located in lower Mesopotamia whilst others locate it further north in upper Mesopotamia, around northern Syria or southeastern Turkey. Theologians suggest that Canaan always belonged to the Israelites but was initially usurped by the descendants of Canaan, resulting in their conquest by Israel as divine punishment.
=== Ulcerative colitis === Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.
=== Public response === Public debate in the Singaporean news media on the death penalty is almost non-existent, although the topic is occasionally discussed in the midst of highly publicised criminal cases. Efforts to garner public opinion on the issue are rare, although it has been suggested that the population is influenced by a legalist philosophy which holds that harsh punishment deters crime and helps maintain social peace and harmony. In October 2007, Senior Minister of State for Law and Home Affairs Ho Peng Kee said in Parliament that "Certain of us may hold the view that the death penalty should be abolished. But in a survey done two years ago, reported in the Straits Times, 95% of Singaporeans feel that the death penalty should stay. This is something which has helped us to be safe and secure all these years and it is only reserved for a very few select offences." Joshua Benjamin Jeyaretnam, an opposition Member of Parliament, was reportedly only given a few minutes to speak in Parliament on the issue before his comments were rebutted by Ho Peng Kee. There were a few instances where in certain high-profile cases, the public would argue for the death penalty to be imposed on those who allegedly committed murder.
Sources: en.wikipedia.org
Serous: Clear straw colored liquid that drains from the wound. This is a normal part of the healing process. Serosanguineous: Small amount of blood is present in the drainage; it is pink in color due to the presence of red blood cells mixed with serous drainage. This is a normal part of the healing process. Sanguineous: This type of drainage contains red blood due to trauma of blood vessels, this may occur while cleaning the wound. Sanguineous drainage is abnormal. Hemorrhaging: This type of drainage contains frank blood from a leaking blood vessel. This will require emergency treatment to control the bleed. This type of drainage is abnormal. Purulent drainage: This type of drainage is malodorous and can be yellow, gray, or greenish in color. This is an indication of an infection.
Guanosine monophosphate synthetase, (EC 6.3.5.2) also known as GMPS is an enzyme that converts xanthosine monophosphate to guanosine monophosphate. In the de novo synthesis of purine nucleotides, IMP is the branch point metabolite at which point the pathway diverges to the synthesis of either guanine or adenine nucleotides. In the guanine nucleotide pathway, there are 2 enzymes involved in converting IMP to GMP, namely IMP dehydrogenase (IMPD1), which catalyzes the oxidation of IMP to XMP, and GMP synthetase, which catalyzes the amination of XMP to GMP.
Vladimir Khatskelevich Khavinson (Russian: Владимир Хацкелевич Хавинсон; 27 November 1946 – 6 January 2024) was a Russian gerontologist and professor who was Treasurer of the European region of the International Association of Gerontology and Geriatrics; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University in Saint Petersburg; Colonel of medical service (USSR, Russia). Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He was engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions was design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by Khavinson. Patenting endogenous peptides is not a common practice as they are considered a "natural product". He authored 196 patents (Russian and international) as well as of 775 scientific publications.
Having worked in industry in the pilot plant of Farbwerke Hoechst AG and then on the surface chemistry of organic pigments, he studied for a PhD at Goethe University in gas-liquid chromatography, a method of separating volatile materials for chemical analysis. He applied his knowledge of chemical engineering science to improving the technology, and developed support-coated open tubular (SCOT) columns which were widely used until supplanted by further developments in capillary columns. He continued to be involved in developments in gas-liquid chromatography in his later career. However, it was while at Harvard Medical School and Yale School of Medicine that he appreciated the need for analytical separation of biological compounds which could not be vaporized, and this led to the application of his particular understanding of separation processes to vastly improve the performance of liquid chromatography. Thus was created high performance liquid chromatography or HPLC, a technique which became a major field of study (and in which he remained a leading figure), and continued to publish till shortly before his death. Together with Imre Molnar and Wayne Melander he developed the framework for describing retention mechanisms in reversed phase chromatography (RPLC), employing the framework of the solvophobic theory. As HPLC and RPLC became the preeminent techniques associated with biochemical analysis, many have suggested that Csaba Horvath inexplicably missed inclusion in the ranks of Nobel laureates.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.